Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing
the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's
Disease with choreic movements.